2024-05-07 13:01:06 ET
Summary
- Novavax will announce its Q1 2024 earnings this Friday, 10th May.
- The company reported revenues of $476m, $1.15bn, $1.98bn, and $984m in the four years since 2020, with heavy net losses in each of those years.
- Novavax plans to focus on commercial markets and move away from advance purchase agreements, with a goal of achieving full approval for its vaccine.
- It's hard to escape the conclusion that having been second best during the pandemic era, Novavax may run into the same problems in a commercial COVID vaccine market.
- The company will update on its BLA application, preparation for the fall vaccine season, APA revenues, and its cost management program, but it's hard to see how Q1 earnings will wow Wall Street or generate upside.
Investment Overview
Novavax ( NVAX ), the Gaithersburg, Maryland headquartered specialist vaccine developer will announce its Q1 2024 earnings this Friday, 10th May.
Novavax is arguably best known for being the company that - very nearly - challenged the supremacy of the messenger-RNA vaccines developed by Moderna ( MRNA ) and Pfizer ( PFE ) / BioNTech ( BNTX ), that earned ~$135bn of revenues during the COVID pandemic era of 2021 - 2023....
Read the full article on Seeking Alpha
For further details see:
Novavax Q1 2024 Earnings Preview: Success In New Commercial COVID Markets Unlikely